Tag: VigiLanz

VigiLanz and Cincinnati Children’s Partner to Commercialize Solution to Minimize Acute Kidney Injury in Pediatrics

VigiLanzVigiLanz and Cincinnati Children’s Hospital Medical Center announces a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for Acute Kidney Injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

Dr. Stuart L. Goldstein
Dr. Stuart L. Goldstein

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Dr. Stuart L. Goldstein, MD, FAAP, FNKF, Director of the Center for Acute Care Nephrology and primary researcher on NINJA.  “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially-available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates a time-consuming manual screening process that includes evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye, and recent renal testing. For medications, manual screening is limited to the last 24 hours, while the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria, as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

Continue Reading

Tackling Patient Safety with Real-Time, Data-Driven Clinical Intelligence

Guest post by Adam Klass, chief technology officer, VigiLanz.

Adam Klass
Adam Klass

Here are some downright chilling patient safety statistics keeping healthcare leaders up at night: Each year more than one million hospital patients – that’s 136 per hour, every day – are affected by sepsis, and 280,000 die. In addition, 82 people in hospitals are affected every hour, every day, by hospital-acquired infections (HAI), and 217 experience a preventable Adverse Drug Event (ADE).

The good news is that an emerging category of technology known as enterprise intelligence resources (EIR) can empower clinicians to more quickly and effectively tackle these infections and ADEs – and even prevent them from occurring in the first place. By integrating and analyzing massive amounts of data generated by multiple sources, EIRs are not only able to identify at-risk patients, but also to tell frontline clinicians in real-time what is happening – and likely to happen – with their patients. Equally important, the EIRs fit seamlessly into clinicians’ workflows, generating only essential alerts.

Built on flexible, interoperable data architectures, EIR platforms extend the value of existing EMRs by integrating real-time clinical and business intelligence with predictive analytics to address sepsis, HAIs and ADEs as well as a wide range of other patient safety and public health risks such as deep vein thrombosis (DVT), venous thromboembolism (VTE), C. difficile (C.Diff), MRSA, surgery site infections, Ebola and MERS. Armed with EIR-provided actionable insights, clinicians can optimize appropriate interventions that improve patient outcomes, reduce patient safety risk and support quality initiatives.

Measurable benefits

Time is of the absolute essence in addressing patient safety risk, particularly in the case of sepsis. Research has shown that the earlier the intervention, the significantly lower the mortality and morbidity.  EIRs can help significantly reduce sepsis risk by enabling clinicians to:

Implementing this approach has been shown to reduce sepsis occurrence by double digits.  Most importantly, patients’ lives are saved. At the same time, reducing sepsis occurrence can also significantly reduce costs, given that sepsis accounts for 40 percent of ICU spending and nearly $29 billion in healthcare expenditures.

Continue Reading